Literature DB >> 9730572

Appearance of nephrotic syndrome following interferon-alpha therapy in a patient with hepatitis B virus and hepatitis C virus coinfection.

M Endo1, H Ohi, T Fujita, I Ohsawa, K Kanmatsuse, Y Yamaguchi.   

Abstract

A 59-year-old woman with hepatitis B surface antigen (HBsAg) and hepatitis C viral (HCV) antibody presented with proteinuria and hematuria. The patient was treated with interferon-alpha (INF-alpha) because plasma aminotransferase levels had been elevated and a liver biopsy had showed chronic active hepatitis. Her urinary protein excretion decreased as liver function normalized and her serum HCV-RNA was negative during treatment. Eleven weeks after completion of INF-alpha treatment, she suddenly presented with nephrotic-range proteinuria, although an improvement in the hepatic function was maintained. Renal pathologic findings were consistent with membranous glomerulonephritis (MGN), and HBsAg was detected in the glomeruli but not HCV. After treatment with prednisolone, her 24-hour protein excretion was below 0.7 g/day. To our knowledge this is the first report on hepatitis B virus MGN with nephrotic syndrome following IFN-alpha therapy for HCV. This suggests that treatment with INF-alpha might affect the immune processes and may be associated with the pathogenic mechanism in this patient.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9730572     DOI: 10.1159/000013367

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  2 in total

1.  Renal adverse effects of interferon-alpha.

Authors:  Slobodan Jankovic
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.